

June 16, 2015

INDIAN PHARMACEUTICAL INDUSTRY AND ITS GROWTH

11

15 180 1 27.5% 2 2014 40%

5 2016 270 3
 API 4
 78 4

FDI
FDI
FIPB

100% FDI
 100% FDI
 100% FDI

FIPB

- a) 1940 1945
- b) 1954 1955
- c) 1970 20
- d) 2013 DPCO; 2011
- e) UCPMP
- f) 1961 40% 18.5%

The Tour d'Horizon of Data Law Implications of Digital Twins

May 29, 2025

Global Capability Centers

May 27, 2025

Fintech

May 05, 2025

2025 Watchlist: Life Sciences Sector India

April 04, 2025

Re-Evaluating Press Note 3 Of 2020: Should India's Land Borders Still Define Foreign Investment Boundaries?

February 04, 2025

INDIA 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 15, 2025

Audio

CCI's Deal Value Test

February 22, 2025

Securities Market Regulator's Continued Quest Against "Unfiltered" Financial Advice

December 18, 2024

Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

NDA Connect

Connect with us at events,
conferences and seminars.

[Click here to view Hotline archives.](#)

Vyapak Desai speaking on the danger of deepfakes | Legally Speaking with Tarun Nangia | NewsX

April 01, 2025

g) 1963

h) VAT

i) 1994 Excise Duty CENVAT

j) 1994

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

Japan.nda(at)nishithdesai.com

1 http://dipp.nic.in/English/Publications/FDI_Statistics/2015/india_FDI_February2015.pdf 2015 6 2
 2 http://dipp.nic.in/English/Investor/Japan_Desk/FDI_Synopsis_Japan.pdf 2015 6 2
 3 2016 270 : 2014 2 16 http://articles.economictimes.indiatimes.com/2014-02-16/news/47379629_1_chronic-therapies-health-awareness-life-sciences 2014 10 16
 4 <https://researchreports.careratings.com/industries/crams-industry.html> 2014 10 16

DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

**Vaibhav Parikh, Partner, Nishith
Desai Associate on Tech, M&A, and
Ease of Doing Business**

March 19, 2025

SIAC 2025 Rules: Key changes & Implications

February 18, 2025